neutral
Recently
Sun Pharma sets FY26 revenue growth outlook in mid-to-high single digits
Sun Pharmaceutical Industries outlined its FY26 outlook, guiding for mid-to-high single digit consolidated revenue growth, driven by specialty products, India formulations strength, and stable performance across global generics operations.
Sun Pharmaceutical Industries said it is targeting mid-to-high single digit consolidated topline growth in FY26, supported by steady performance across specialty, India formulations, and global generics businesses. The company highlighted ongoing investments in R&D, specialty portfolio expansion, and market penetration initiatives while monitoring regulatory developments and pricing dynamics across key international markets.